Search research articles
Contact Us
Filters
Showing results (41-50 of 81) with videos related to
Page
of 9
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
December 19, 2025
Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation
Borja Puertas, Elena Alejo, José J Pérez-Morán, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2017
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Juan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales, et al.
Blood
|
April 13, 2016
Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis
Bruno Paiva, Joaquin Martinez-Lopez, Luis A Corchete, et al.
Blood Advances
|
December 11, 2025
Real-world evidence of measurable residual disease assessment in multiple myeloma
Maria Teresa Cedena, Noemi Puig, Bruno Paiva, et al.
Blood
|
January 13, 2016
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
Bruno Paiva, Luis A Corchete, Maria-Belen Vidriales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2024
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
Marta Lasa, Laura Notarfranchi, Cristina Agullo, et al.
Blood Advances
|
September 29, 2021
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
Cirino Botta, Catarina Maia, Juan-José Garcés, et al.
Blood
|
November 8, 2019
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
Luzalba Sanoja-Flores, Juan Flores-Montero, Noemi Puig, et al.
British Journal of Haematology
|
June 18, 2026
Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival
Borja Puertas, Irene Padilla, Elena Alejo, et al.
Cancers
|
April 30, 2021
B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients
Robéria Mendonça de Pontes, Juan Flores-Montero, Luzalba Sanoja-Flores, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 81) with videos related to
Sort By:
Page
of 9
Clinical Lymphoma, Myeloma & Leukemia
|
December 19, 2025
Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation
Borja Puertas, Elena Alejo, José J Pérez-Morán, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2017
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Juan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales, et al.
Blood
|
April 13, 2016
Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis
Bruno Paiva, Joaquin Martinez-Lopez, Luis A Corchete, et al.
Blood Advances
|
December 11, 2025
Real-world evidence of measurable residual disease assessment in multiple myeloma
Maria Teresa Cedena, Noemi Puig, Bruno Paiva, et al.
Blood
|
January 13, 2016
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
Bruno Paiva, Luis A Corchete, Maria-Belen Vidriales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2024
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
Marta Lasa, Laura Notarfranchi, Cristina Agullo, et al.
Blood Advances
|
September 29, 2021
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
Cirino Botta, Catarina Maia, Juan-José Garcés, et al.
Blood
|
November 8, 2019
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
Luzalba Sanoja-Flores, Juan Flores-Montero, Noemi Puig, et al.
British Journal of Haematology
|
June 18, 2026
Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival
Borja Puertas, Irene Padilla, Elena Alejo, et al.
Cancers
|
April 30, 2021
B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients
Robéria Mendonça de Pontes, Juan Flores-Montero, Luzalba Sanoja-Flores, et al.
Page
of 9